• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

161.01 -0.49 (-0.30%)
Streaming Delayed Price Updated: 11:48 AM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount ↗
August 05, 2026
Via Chartmill
News headline image
Neurocrine (NBIX) Q2 2026 Earnings Call Transcript ↗
August 03, 2026
Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%. 
Via The Motley Fool
Topics Earnings
News headline image
Neurocrine Biosciences Q2 Earnings Call Highlights ↗
July 31, 2026
Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the... 
Via MarketBeat
Topics Earnings
News headline image
Neurocrine (NBIX) Q2 2026 Earnings Call Transcript ↗
July 30, 2026
Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%. 
Via The Motley Fool
Topics Earnings
Neurocrine Biosciences (NASDAQ:NBIX): Strong Growth Stock with Technical Breakout Setup ↗
July 27, 2026
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Stock ↗
July 25, 2026
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Offers a High Growth Momentum Breakout Setup ↗
July 20, 2026
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screening ↗
July 16, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen ↗
July 11, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shines in the "Little Book That Makes You Rich" Screen ↗
July 04, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Growth and Technical Breakout Setup ↗
July 01, 2026
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Profile of a Classic GARP Stock Under the Peter Lynch Framework ↗
June 24, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Decent Value Play with Strong Fundamentals ↗
June 20, 2026
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout Candidate ↗
June 16, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book Strategy ↗
June 10, 2026
Via Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Score ↗
June 08, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Peter Lynch GARP Opportunity with Strong Growth and a PEG Ratio of 0.82 ↗
June 03, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and Bull Flag Breakout Setup ↗
May 29, 2026
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Momentum Breakout Setup ↗
May 26, 2026
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Shows Affordable Growth Potential ↗
May 22, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals ↗
May 19, 2026
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a Peter Lynch-Style GARP Opportunity ↗
May 12, 2026
Via Chartmill
News headline image
Neurocrine (NBIX) Q1 2026 Earnings Transcript ↗
May 05, 2026
Neurocrine (NBIX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Neurocrine Biosciences (NASDAQ:NBIX) Smashes Q1 Estimates with 44% Sales Surge ↗
May 05, 2026
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
May 05, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
Neurocrine Biosciences Inc (NASDAQ:NBIX) Qualifies for Affordable Growth Screen with Strong GARP Profile ↗
April 30, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical Setup ↗
April 17, 2026
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock ↗
April 09, 2026
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
April 27, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avanos Medical, Inc. (NYSE – AVNS), Leggett & Platt, Incorporated (NYSE – LEG), Soleno Therapeutics, Inc. (Nasdaq – SLNO), Forian, Inc. (Nasdaq – FORA)
April 15, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap